Gabriela Morales-Rivera is an associate in the firm's Business Law Department and a member of its Technology and Life Sciences groups. Ms. Morales-Rivera represents public and private companies in startup and formation matters, venture capital financing, initial public offerings and capital markets transactions, strategic investments, and other complex transactions.

She also represents a number of publicly traded biotechnology companies in ongoing SEC compliance and corporate governance matters. Advising companies throughout the full range of the corporate life cycle, Ms. Morales-Rivera has worked with many of her company-side clients since their initial founding and funding. She joined Goodwin in 2015.

Areas of Practice
TÄTIGKEITSFELDER
Domaines D’Expertise
业务范围

Experience

ERFAHRUNG

EXPÉRIENCE

工作经历

Ms. Morales-Rivera’s recent client representations include the following:

General Corporate Counseling and Significant Transactions

  • Relay Therapeutics in connection with:
    • its $63 million Series B financing
    • its $400 million Series C financing
    • its $460 million initial public offering
    • its collaboration and license agreement with Genentech for the development and commercialization of RLY-1971
    • its acquisition of ZebiAI for $85 million upfront
  • Forma Therapeutics in connection with:
    • its $100 million Series D financing
    • its $319.3 million initial public offering
    • its $275.8 million follow-on offering
  • Nimbus Therapeutics in connection with:
    • the $1.2 billion sale of its ACC inhibitor program to Gilead Bioscience
    • its multi-target strategic alliance with Celgene Corporation in immunology
    • its $65 million Series 2018 preferred stock financing
    • its $43 million Series B financing
    • its $60 million private financing round from life science investors RA Capital Management and BVF Partners L.P.
    • its $105 million private stock financing
  • ElevateBio in connection with:
    • its $150 million Series A financing
    • its $193 million Series B financing
    • its $525 million Series C financing
  • Akero Therapeutics in connection with:
    • its $65 million Series A financing
    • its $70 million Series B financing
    • its $105.8 million initial public offering
    • its $216.4 million follow-on public offering
  • Accent Therapeutics $63.0 million Series B financing
  • MoMa Therapeutics in its $86.0 million Series A financing
  • ROME Therapeutics in its $50 million Series A financing
  • Allovir in its $120 million Series B financing
  • Aptinyx in connection with:
    • its $65 million Series A financing
    • its $70 million Series B financing
    • its $117.8 million initial public offering
  • Cullinan Oncology in its:
    • $98.5 million Series B Financing
    • $131.2 million Series C Financing
    • $287.4 million initial public offering
  • Exosome Diagnostics in connection with:
    • its $30 million Series C financing
    • its sale to Bio-Techne Corporation
  • Kymera Therapeutics in connection with:
    • its $30 million Series A financing
    • its $65 million Series B financing
    • its research and development collaboration with Vertex Pharmaceuticals
    • its $200 million initial public offering
  • Neon Therapeutics in connection with:
    • its $106 million Series B financing
    • its $100 million initial public offering
    • its $97 million sale to BioNTech
  • Tango Therapeutics in connection with:
    • its $55 million Series A financing
    • its $60 million Series B financing
    • its $40 million equity financing

Public Company Representation and Capital Markets Transactions

  • Adicet Bio, Inc. (formerly resTORbio, Inc.) in connection with:
    • its $97.8 million initial public offering
    • its $50 million follow-on offering
    • its $152 million follow-on offering and concurrent private placement
  • Intellia Therapeutics in connection with:
    • its $150 million follow-on offering
    • its $115 million follow-on offering
    • its expanded licensing agreement with Regeneron Pharmaceuticals
    • its $600 million follow-on offering
  • Talaris Therapeutics in its $150 million initial public offering
  • Sage Therapeutics in its $575 million and $345 million follow-on offering
  • Repligen Corp. in connection with:
    • its acquisition of TangenX Technology Corporation
    • its acquisition of Spectrum, Inc.
    • its $138 million follow-on offering
Professional Experience

While attending law school, Ms. Morales-Rivera interned for the Honorable Juan R. Torruella of the First Circuit Court of Appeals.

Ms. Morales-Rivera is a member of the Boston and American Bar Associations as well as the Hispanic National Bar Association.

Recognition

Ms. Morales-Rivera has been recognized by The Best Lawyers in America Ones to Watch for her work in Corporate and Technology Law 2022.

In The News

MELDUNGEN

ACTUALITÉS

相关新闻

Credentials

WERDEGANG

RÉFÉRENCES

专业资格

Education

J.D., 2015
Boston University School of Law
B.A., 2012
Swarthmore College
(with high honors)

Admissions

Bar

Massachusetts
Profile Image
Get In Touch
Kontakt
NOUS CONTACTER
联系我们
Our clients rely on us for world-class advisory services, counsel on complex transactional work and high-stakes litigation. Specializing in matters involving the financial, life sciences, private equity, real estate, and technology industries, we use a collaborative, cross-disciplinary approach to resolve our clients’ most challenging issues. To find out more, please contact us.

Unsere Kunden verlassen sich auf unsere erstklassige Beratung, vor allem im Hinblick auf komplexe Transaktionen und High-Stakes-Prozesse. Spezialisiert auf Angelegenheiten der Finanz-, Life-Sciences-, Private-Equity-, Immobilien-und Technologie-Branchen, verwenden wir einen kooperativen und interdisziplinären Ansatz, um Fragen unserer Kunden auch in extremen Spezialsituationen einer Lösung zuzuführen. Sie wollen mehr erfahren? Kontaktieren Sie uns gerne.

Nos équipes interviennent aux côtés de nos clients, industriels, fonds d’investissement, startups, institutions financières et dirigeants, dans le cadre de transactions et de contentieux complexes, et apportent des conseils de tout premier plan dans les secteurs financiers, des Sciences de la Vie, du Private Equity, de l’immobilier et des technologies. Nous traitons les dossiers juridiques de manière intègre, ingénieuse, souple et audacieuse pour répondre efficacement aux enjeux propres à chacun de nos clients, quels que soient la taille de l’opération et le secteur d’activité. Pour en savoir plus, contactez-nous.

客户信赖我们世界一流的咨询服务,希望获得针对复杂事务性工作与高风险诉讼的建议。我们通过协作式、跨领域的工作方法来解决客户最棘手的问题,涵盖金融、生命科学、私募股权、不动产和技术等多个行业。如需更多信息,请与我们联系。

Search Other Lawyers
ANWALTSSUCHE
Recherche par Pratique
搜寻其他律师